Cumberland Partners Ltd Trims Stake in IQVIA Holdings Inc. $IQV

Cumberland Partners Ltd decreased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 21.3% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 10,005 shares of the medical research company’s stock after selling 2,713 shares during the quarter. Cumberland Partners Ltd’s holdings in IQVIA were worth $1,706,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Ameliora Wealth Management Ltd. acquired a new stake in shares of IQVIA during the fourth quarter valued at $25,000. Financial Freedom LLC acquired a new position in IQVIA in the 1st quarter valued at about $25,000. Ascentis Independent Advisors purchased a new position in IQVIA in the 1st quarter valued at about $25,000. International Assets Investment Management LLC purchased a new position in IQVIA in the 4th quarter valued at about $27,000. Finally, Gilpin Wealth Management LLC acquired a new stake in shares of IQVIA during the 4th quarter worth about $27,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently weighed in on IQV. Robert W. Baird boosted their price objective on shares of IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a research report on Wednesday, July 1st. Morgan Stanley restated an “equal weight” rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Evercore reiterated an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a report on Wednesday, April 8th. HSBC restated a “buy” rating and set a $240.00 price objective on shares of IQVIA in a report on Monday, July 6th. Finally, Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. Thirteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $225.71.

IQVIA Trading Up 0.4%

IQV stock opened at $208.22 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The company has a market cap of $34.75 billion, a price-to-earnings ratio of 25.80, a PEG ratio of 1.86 and a beta of 1.20. The business has a fifty day simple moving average of $188.23 and a 200-day simple moving average of $187.38. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $247.04.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter last year, the firm earned $2.70 earnings per share. The firm’s revenue for the quarter was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities research analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its Board of Directors has initiated a share buyback program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to buy up to 6.8% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its shares are undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.